Chemical subgroup
L01FC – CD38 (Cluster of Differentiation 38)-Inhibitoren
16Decisions
18Patient groups
Added benefit by patient group
- Considerable4
- Minor6
- Non-quantifiable1
- Not proven7
Decisions, newest first
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19DarzalexDaratumumabMinor
- 2026-02-19SarclisaIsatuximabNot proven
- 2025-08-21DarzalexDaratumumabConsiderable
- 2025-08-07SarclisaIsatuximabMinor
- 2025-05-15DarzalexDaratumumabNot proven
- 2024-05-16DarzalexDaratumumabConsiderable
- 2022-09-15DarzalexDaratumumabConsiderable
- 2022-03-18DarzalexDaratumumabConsiderable
- 2022-02-03DarzalexDaratumumabMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-01-20DarzalexDaratumumabNot proven
- 2021-11-04SarclisaIsatuximabNot proven
- 2021-11-04SarclisaIsatuximabMinor
- 2020-08-20DarzalexDaratumumabNon-quantifiable
- 2020-08-20DarzalexDaratumumabMinor
- 2018-02-15DarzalexDaratumumabNot proven
Data status: 2026-10-29